Research programme: RSV fusion inhibitors - Johnson and Johnson/Tibotec

Drug Profile

Research programme: RSV fusion inhibitors - Johnson and Johnson/Tibotec

Alternative Names: TMC-353121

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development; Tibotec BVBA
  • Developer Janssen Research & Development
  • Class
  • Mechanism of Action Viral fusion protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Respiratory syncytial virus infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Respiratory-syncytial-virus-infections in Europe (IV)
  • 03 Oct 2007 Data presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapeutics (ICAAC-2007) added to the Pharmacokinetics and Viral Infections pharmacodynamics sections
  • 03 Oct 2006 Preclinical development for Respiratory syncytial virus infections in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top